Sort by:

• Highly Influential Citations
• Citations
• Acceleration
• Velocity
• Recency

Learn More

In vitro and in vivo pharmacological characterization of BIIL 284, a novel and potent leukotriene B(4) receptor antagonist.

• Franz W Birke, Christopher J Meade, Ralf Anderskewitz, G. A. Speck, H. -M. Jennewein
• The Journal of pharmacology and experimental…
• 2001

BIIL 284 is a new LTB(4) receptor antagonist. It is a prodrug and has negligible binding to the LTB(4) receptor. However, ubiquitous esterases metabolize BIIL 284 to the active metabolites BIIL 260… (More)

Inhibition of a store-operated Ca2+ entry pathway in human endothelial cells by the isoquinoline derivative LOE 908.

• A Encabo, Christoph Romanin, Franz W Birke, Walter R. Kukovetz, Klaus Groschner
• British journal of pharmacology
• 1996

1. The novel cation channel blocker, LOE 908, was tested for its effects on Ca2+ entry and membrane currents activated by depletion of intracellular Ca2+ stores in human endothelial cells. 2. LOE 908… (More)

Serum PAF-acetylhydrolase in severe renal or hepatic disease in man: relationship to circulating levels of PAF and effects of nephrectomy or transplantation.

• Christopher J Meade, Franz W Birke, Sylvia Metcalfe, Ceri Watson, N. S. D. Jamieson, Guy Neild
• Journal of lipid mediators and cell signalling
• 1994

(1) PAF-acetylhydrolases form a major pathway for the degradation of platelet-activating factor (PAF). Here we investigate the role of the kidney and the liver in the control of PAF-acetylhydrolase… (More)

Radioligand binding of antagonists of platelet-activating factor to intact human platelets.

• Dieter Ukena, Gordon Dent, Franz W Birke, C Robaut, Gerhard Walter Sybrecht, Peter J Barnes
• FEBS letters
• 1988

Two new antagonists of platelet-activating factor (PAF), the pyrrolothiazole derivative 52770 RP and the triazolodiazepine WEB 2086, have been studied as radioligands in intact human platelets.… (More)

Histopathology of tumour associated sarcoid-like stromal reaction in breast cancer

• Roland Bässler, Franz W Birke
• Virchows Archiv A
• 1988

In 5 cases of invasive ductal and lobular carcinoma of the breast multiple epithelioid and giant cell containing granulomas were detected, localized mainly in circumferential regions, but also in the… (More)

Novel ligands for the chemokine receptor-3 (CCR3): a receptor-modeling study based on 5D-QSAR.

• Angelo Vedani, Max Dobler, Horst Dollinger, Kai-Malte Hasselbach, Franz W Birke, Markus A. Lill
• Journal of medicinal chemistry
• 2005

We recently reported the development of a receptor-modeling concept based on 5D-QSAR (quantitative structure-activity relationships) and which explicitly allows for the simulation of induced fit. In… (More)

Inhibition of human HL-60 cell responses to chemotactic factors by antisense messenger RNA depletion of G proteins.

• Edward J. Goetzl, Richard S. Shames, +4 authors Sungkwan An
• The Journal of biological chemistry
• 1994

Chemotactic factors bound to receptors of the seven-transmembrane domain family signal leukocytes through associated guanine nucleotide-binding (G) proteins. Human leukocytes of the HL-60 line, which… (More)

Pharmacodynamics, pharmacokinetics and safety profile of the new platelet-activating factor antagonist apafant in man.

• Hans Michael Brecht, Waclaw Stefan Dr Adamus, Hubert Otto Heuer, Franz W Birke, E. R. Kempe
• Arzneimittel-Forschung
• 1991

Platelet-activating factor (PAF) is a unique phospholipid mediator with multifunctional properties. Evidence generated in experimental studies suggests that PAF plays a pathogenetic role in… (More)

Hetrazepine PAF antagonists.

• Kenji Ikegami, Christopher J Meade, Hubert Otto Heuer, Franz W Birke
• Journal of lipid mediators
• 1992

Hetrazepines such as WEB-2086 or WEB-2170 are potent, specific, competitive PAF antagonists binding at the same site as the PAF molecule. Despite their structural similarity to known hypnotic drugs… (More)

Pyrrolidinohydroquinazolines--a novel class of CCR3 modulators.

• Ralf Anderskewitz, Rolf Bauer, +4 authors Franz W Birke
• Bioorganic & medicinal chemistry letters
• 2005

A novel class of CCR3 modulators is described. Starting with lead compound 4a (K(i): 110 nM), which turned out to be an antagonist of eotaxin at the CCR3 receptor, further optimization led to… (More)

• ‹
• 1
• 2
• ›